Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk…
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of…
AI innovation in population health continues to fuel Lightbeam's momentum, earning recognition among the fastest-growing private companies in America DALLAS,…
Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va.,…
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted…
Founded by a team of physicians and AI experts, EasyPA launched the nation's first fully operational prior authorization (PA) platform…
Technology-enabled solution expands access to high-touch, personalized dementia care at home BOSTON, Aug. 12, 2025 /PRNewswire/ -- Neuroglee Health, a…
NEW YORK, NY / ACCESS Newswire / August 12, 2025 / Inc., the leading media brand and playbook for the…